The immunopotentiation effects of the bifunctional radiosensitizer KIN-806 in comparison with its analogs KIN-804 and KIN-844.

KIN-806 is one of the 2-nitroimidazole derivative hypoxic cell radiosensitizers. Its radiosensitizing effects and the degree of lung metastasis detected were evaluated and compared with its analogs KIN-804 and KIN-844. The immune reactions induced by these radiosensitizers were also analyzed. Female C3H/He mice and SCCVII tumor cells were used. Seventeen days after inoculation of SCCVII tumor cells into the animals, 0.4 g/kg of KIN-806, KIN-804, and KIN-844 was administered to each radiosensitizer group 30 min before 40 Gy was delivered as local irradiation. In each group, KIN-806, KIN-804, and KIN-844 markedly suppressed tumor regrowth in comparison with animals that received irradiation alone. There was no significant difference in the radiosensitizing effects among these three radiosensitizers. A marked suppression of lung metastasis and macrophage/T-lymphocyte infiltration into the tumor were observed only in the KIN-806-administered groups, regardless of the presence or absence of radiation therapy. It therefore appears likely that the lung metastasis suppression was caused by the immune reaction elicited by KIN-806, which is an excellent immunopotentiator as well as an effective radiosensitizer.
AuthorsT Inomata, Y Ogawa, A Nishioka, N Hamada, S Ito, S Kariya, S Yoshida, H Nagasawa, H Hori, S Inayama
JournalOncology reports (Oncol Rep) 1999 Nov-Dec Vol. 6 Issue 6 Pg. 1209-12 ISSN: 1021-335X [Print] GREECE
PMID10523682 (Publication Type: Comparative Study, Journal Article)
Chemical References
  • Hydroxamic Acids
  • KIN 806
  • Nitroimidazoles
  • Radiation-Sensitizing Agents
  • 2-nitroimidazole-1-methylacetohydroxamate
  • Animals
  • Cytotoxicity, Immunologic
  • Female
  • Hydroxamic Acids (administration & dosage)
  • Lung Neoplasms (drug therapy, immunology, radiotherapy, secondary)
  • Mice
  • Mice, Inbred C3H
  • Neoplasms, Experimental (drug therapy, immunology, pathology, radiotherapy)
  • Nitroimidazoles (administration & dosage)
  • Radiation-Sensitizing Agents (administration & dosage)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: